Prof. Kyle A. Emmitte is a Professor and Chair of the Department of Pharmaceutical Sciences at the University of North Texas Health Science Center at Fort Worth. He is a member of the American Chemical Society, American Association of Colleges of Pharmacy, and American Association of Pharmaceutical Scientists and routinely serves as a reviewer for several scientific journals within the fields of medicinal chemistry and drug discovery. He received a BS in chemistry from Texas A&M University in 1996 and a PhD in Organic Chemistry from the University of North Carolina at Chapel Hill in 2001. He has received the Pharmaceutical Sciences Professor of the Year award from the UNT System College of Pharmacy Student Government Association five times (2018–22). In 2014, the Vanderbilt Center for Technology Transfer & Commercialization selected his team's mGlu2 and mGlu3 NAM work as one of the 10 Cool Inventions from 2014. In 2008, he received a GSK Silver Award for project and chemistry team leadership leading to the discovery of GSK1904529, an IGF-1R clinical candidate. In 2004, he received the GSK Exceptional Science Award for sustained and key contributions to the discovery of the PLK inhibitor clinical candidate GSK461364. His primary research interests encompass areas related to the design and optimization of biologically active small molecules to serve as in vivo probes, drug discovery leads, and optimized preclinical compounds.